2011 Fiscal Year Final Research Report
Exploration of a prognostic biomarker for lung cancer as personalized medicine using a genome-wide approach
| Project/Area Number |
21591001
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | EZH2 / 非小細胞肺癌 / 予後予測因子 / ゲノムワイド / 個別化医療 |
|---|
| Research Abstract |
Using immunohistochemistry for EZH2, we showed that the EZH2-expressing group reduced survival of stage I NSCLC compared with the non-EZH2-expressing group. In COX proportional hazard models, the non-EZH2-expressing group was independently associated with prolonged survival. These results suggest that EZH2 can be a novel predictive factor for prognosis in postsurgical NSCLC at stage I. Furthermore, using shRNA-mediated knockdown of EZH2 expression, in vitro cell growth assay and matrigel invasion assay showed that the suppression of EZH2 expression inhibited cellular proliferation and reduced invasion and metastatic potentials. Thus, EZH2 may function as an oncogene.
|
